anti-CD19 CAR-T
Sponsors
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Nanchang University, Zhejiang University
Conditions
Acute Lymphoblastic Leukemia ,LymphomasAdult Acute Lymphoblastic Leukemia in RemissionAdvanced Hepatocellular CarcinomaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaHematopoietic/Lymphoid CancerRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular Lymphoma
Phase 1
Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
NCT02685670
Start: 2016-02-29End: 2019-12-31Target: 20Updated: 2017-03-16
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
NCT03110640
Start: 2016-10-01End: 2021-09-30Target: 20Updated: 2019-11-27
Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas
NCT04196205
Start: 2019-12-01End: 2021-08-01Target: 20Updated: 2019-12-12
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
RecruitingNCT06676982
Start: 2025-01-10End: 2026-08-31Target: 12Updated: 2025-12-15